Terrific news! This is how it starts...a trickle of new agreements that build to a formidable revenue source for the company. I like how niche this is.. leaving tons of room for more agreements like it.
Does anyone know the Australian process for approving animal vaccines? I wonder how soon this JV may bear fruit?
20% of net sales, plus other fees.. the C1 platform can become a formidable revenue source for Dyadic. Imagine similar deals on dozens of drugs and vaccines, all the while they retain IP. Talk about multiple shots on goal .. in their case it's literally hundreds of shots of goal, all without them having to pay for expensive trials. This is a multi-billion dollar platform in the making. Patience here will be generously rewarded, IMO. Market cap today just $90MM.
News 
Market Data 
Discover 
